Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist.
The glucagon analog [l-N alpha-trinitrophenylhistidine, 12-homoarginine]-glucagon (THG) was examined for its ability to lower blood glucose concentrations in rats made diabetic with streptozotocin. In vitro, THG is a potent antagonist of glucagon activation of the hepatic adenylate cyclase assay system. Intravenous bolus injections of THG caused rapid decreases (20 to 35 percent) of short duration in blood glucose. Continuous infusion of low concentrations of the inhibitor led to larger sustained decreases in blood glucose (30 to 65 percent). These studies demonstrate that a glucagon receptor antagonist can substantially reduce blood glucose levels in diabetic animals without addition of exogenous insulin.
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy*; D005934:Glucagon / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006943:Hyperglycemia / Q000188:drug therapy*; D008297:Male; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects*; D018027:Receptors, Glucagon; D013329:Structure-Activity Relationship
D011956:Receptors, Cell Surface; D018027:Receptors, Glucagon; C033953:glucagon, N(alpha)-trinitrophenyl-His(1)-homo-Arg(12)-; D005934:Glucagon